LENZ Therapeutics (LENZ) versus Its Competitors Head-To-Head Comparison

LENZ Therapeutics (NASDAQ:LENZ) is one of 289 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare LENZ Therapeutics to related companies based on the strength of its analyst recommendations, earnings, dividends, institutional ownership, profitability, valuation and risk.

Risk & Volatility

LENZ Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, LENZ Therapeutics’ peers have a beta of 1.10, meaning that their average share price is 10% more volatile than the S&P 500.

Valuation and Earnings

This table compares LENZ Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
LENZ Therapeutics	N/A	-$124.65 million	-1.05
LENZ Therapeutics Competitors	$545.62 million	-$37.02 million	8.91

LENZ Therapeutics’ peers have higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and price targets for LENZ Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	0	0	5	0	3.00
LENZ Therapeutics Competitors	1435	4548	11893	208	2.60

LENZ Therapeutics currently has a consensus target price of $31.33, indicating a potential upside of 90.36%. As a group, “Biological products, except diagnostic” companies have a potential upside of 66.61%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe LENZ Therapeutics is more favorable than its peers.

Insider & Institutional Ownership

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 38.4% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 16.3% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares LENZ Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-33.12%	-27.96%
LENZ Therapeutics Competitors	-4,533.48%	-225.14%	-44.84%

Summary

LENZ Therapeutics beats its peers on 8 of the 13 factors compared.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.